As a result, one of the pillars of anti-cancer therapy is based on counteracting pro-angiogenic factors such as Vascular Endothelial Growth Factor A (VEGF-A), angiopoietin 2 (Ang-2) and Delta-like Ligand 4 (DLL4) [83,84]. This evidence concerns the gene VEGFA and cancer.